January 12, 2014 |
Buying prescription drugs overseas is back on the national agenda. Maine recently allowed residents to buy drugs from pharmacies in Canada, England, New Zealand, and Australia, triggering a lawsuit from the pharmaceutical industry. And a bill introduced last month in Congress would let people buy drugs from countries with safety rules similar to our own. Prescription drug prices here are generally higher than anywhere else in the world. While it is technically illegal for U.S. citizens to import drugs manufactured here and exported, it is a fact of today's world.
December 12, 2013 |
Teva Pharmaceutical Industries Ltd., which is awash in turmoil, told financial analysts Tuesday that it projects that about $500 million in 2014 revenue hinges on how soon the Food and Drug Administration approves generic versions of Teva's top-selling multiple sclerosis drug, Copaxone. Teva is a corporate contradiction within the pharmaceutical industry because it is the world leader in generic-drug revenue, but about 20 percent of its revenue comes from one patent-protected, original medication that produces higher profits per unit.
November 28, 2013 |
Turmoil continues at Teva Pharmaceutical Industries Ltd., which this week tried to dispel a report of company expectations of a dramatic decline in profit for its best-selling drug, and last week was suggested to be a possible takeover target by other drugmakers. On Oct. 30, chief executive officer Jeremy Levin resigned after a dispute with the board of directors, which didn't seem to mind his departure. "In a low-interest-rate environment, Teva is now sitting in a very attractive position for an acquirer," Bernstein Research analyst Ronny Gal wrote in a recent note to clients.
March 13, 2013 |
Michael E. Yasick, 49, of Downingtown, a leader in the pharmaceutical industry for more than two decades, died Friday, March 8, of a heart attack at Paoli Hospital. Mr. Yasick worked from 1988 to 2001 for GlaxoSmithKline, including a stint in London, before joining Shire Pharmaceuticals in 2004 as head of the gastrointestinal business unit. His specialty was developing medicines for treatment of infections, central nervous system ailments, gastrointestinal problems, and attention deficit hyperactivity disorder (ADHD)
August 21, 2011 |
Maybe the 15 women chatting over coffee at the Wegmans supermarket cafe in Malvern should start their own pharmaceutical firm. They have the brain power, if not the capital. A scientist who spent 19 years in drug development sat a few tables away from a coordinator of clinical trials. A few managed pharmaceutical finances, and one administered a $2.7 billion global research and development budget. One handled drug pricing and another edited marketing materials. The former human resources person squeezed in next to the woman who once worked in supply logistics.
June 24, 2011 |
WASHINGTON - The Supreme Court gave the pharmaceutical industry a pair of victories on Thursday, shielding the makers of generic drugs from most lawsuits by injured patients and declaring that drug manufacturers had a free-speech right to buy private prescription records to boost their sales pitches to doctors. In both decisions, the court's conservative bloc formed the majority, and most of its liberals dissented. About 75 percent of the prescriptions written in the U.S. are for lower-cost generic versions of brand-name drugs.
August 11, 2009 |
I'M OUTRAGED at the White House's apparent coziness with Big Pharma. Our medical industry is driven by drug profits and over the last two decades, the pharmaceutical industry has been driving health care costs to unsustainable levels. Some chronically ill patients and many of the elderly say they can't afford their medication if they don't carry gold-plated insurance to pay for it. So I'm not impressed that Big Pharma will spend $150 million on TV ads, or its pledge to cut drug costs by $80 billion, without first learning the specifics of the deal that the industry cut with the White House, since we can blame the drug companies' hefty prices as one of several causes of unaffordable health care for millions.
March 2, 2008 |
It's a year of shifting allegiances for the pharmaceutical industry, which has leaned Republican in recent years. The presumptive GOP candidate, John McCain, views the drug industry as "big bad boys" and vows to curb their influence. And the candidate with the most pharma contributions at the moment is Democrat Hillary Rodham Clinton, a lightning rod for criticism during her husband's health-reform effort of the 1990s. "It's quite clear the industry bets on candidates like they bet on horses," said Uwe Reinhardt, a health-economics professor at Princeton University.
January 28, 2006
Health-care partners Your article on the relationship between pharmaceutical industry representatives and Penn Health System ("Physician, steel thyself from gifts," Jan. 25) deserves clarification. Following a symposium in 2004 on this subject, it was our intention to remodel our relationship with the pharmaceutical industry. Our symposium occurred against an internal backdrop of rigorous decision-making about new drugs and long-standing policies to restrict the movements and activities of pharmaceutical company representatives.
January 13, 2006
LAST WEEK, I had to pay cash for my prescription because either Blue Cross' or our government's computers weren't updated to the changes in Medicare. Added to that aggravation is the unabashed greed the pharmaceutical industry expects us to support. My prescription plan has an annual cap. Because of that, I know the retail cost was $173 last year. This time, I had to pay $200. That increase, I suspect, is due solely to the federal government's paying either the whole freight or the difference in private coverage.